39 results about "Reverse cholesterol transport" patented technology

The present invention relates to biochemical methods for determining reverse cholesterol transport. Specifically, the rates of the two arms of reverse cholesterol transport (HDL or first arm and post-HDL or second arm) are obtained by measuring the flow of unlabeled cholesterol from tissues into plasma HDL and from plasma HDL to bile acids.

The present invention shows that pharmacological up regulation of SRB-1, ABC-A1 and LCAT genes collectively can be used to promote reverse cholesterol transport and increase circulating HDL cholesterol as treatment for atherosclerosis and related cardiovascular disorders.

The invention belongs to the medical technical field, and relates to a new function of high density lipoproteins (HDLs) of different structures as a targeted carrier for a liposoluble cardiovascular medicament. The recombinant HDL can be taken as a cholesterol receptor for receiving excess extra-hepatic cellular cholesterol and transporting the cholesterol to liver for metabolism, thus achieving the purpose of treating cardiovascular or arteriosclerotic disease. In the invention, the HDLs or lipid components thereof are recombined into the carrier for the liposoluble medicament in vitro so as to achieve dual functions of medicament delivery to an atherosclerosis focal area on a vascular wall and reverse cholesterol transport (RCT), which provides a new effective way for treating cardiovascular disease.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and / or prevention of disease conditions associated with hypercholesterolemia.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

A method of determining a potential of a nondiabetic or diabetic patient to benefit from reverse cholesterol transport therapy for treatment of a vascular complication, followed by methods and compositions of treating the diagnosed vascular complications comprising determining a haptoglobin phenotype of the patient. Reverse cholesterol transport therapy includes inhibition of cholesteryl ester transport protein, such as by using the compound torcetrapib.

The invention relates to the application of isoflavones red clover (form 1) and genistein (form 2). The invention is utilized for the preparation of medicine through strengthening the reverse cholesterol transport processed treatment and / or preventing the atherosclerosis. The medicine of strengthing the reverse cholesterol transport processed treatment and / or preventing the atherosclerosis comprises the medicine presented the liveness through the up-regulation of the high density lipoprotein receptor CLA-1 / SR-BI and the ATP cassette antigen ABCA1. The invention also relates to the drug composition of strengthening the reverse cholesterol transport processed treatment and / or preventing the atherosclerosis, the active constituents efficient chosen from the isoflavones red clover (form 1) and genistein (form 2) provided on the drug composition and optional carrier which is able to be adopted by the pharmacy.

Belonging to the field of pharmacy, the invention relates to application of a Chinese prickly ash extract to preparation of medicaments for regulating cholesterol metabolism. In particular, the invention relates to regulation of cholesterol metabolism by a petroleum ether extract, an ethyl acetate extract and an n-butanol extract in high cholesterol and inflammation states. In vitro experiments show that in high cholesterol condition, the extracts can reduce the content of total cholesterol and secretion of an apolipoprotein B, inhibit the expression of related genes and proteins in a cholesterol biosynthesis pathway in cells, increase the expression of related genes or proteins in a reverse cholesterol transport process in cells. In vivo experiments prove that the ethyl acetate extract and n-butanol extract have anti-inflammatory activity, and improve the accumulation of inflammation-induced cholesterol in the liver by affecting expression of a liver X receptor-alpha and an ATP-binding cassette transporter gene 1. The invention further provides monomer (-)-syringaresinol-4-O-beta-D-glucoside isolated from the n-butanol extract and application thereof to regulation of cholesterol metabolism.

Disclosed are compositions and methods for treating cardiovascular disease and reducing the adverse effects induced by the administration of statins. In particular, disclosed is the use of antisense compounds to augment the expression of mirR-33 and associated genetic elements. In particular methods of the treatment of cardiovascular disease and the modulation of miR-33 levels is disclosed as well as treatment of the secondary effects including cholestasis, induced by the administration of statins is disclosed. Also disclosed is the treatment of Benign Recurrent Intrahepatic Cholestasis and reverse cholesterol transport. The disclosed methods and compositions may be practiced separately or co-administered with satins to reduce or treat statin induced secondary effects.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

The invention relates to application of a histone deacetylase inhibitor compound in preparing a medicament for treating and / or preventing atherosclerosis by strengthening a reverse cholesterol transport mechanism, wherein a histone deacetylase inhibitor is trichostatin A shown in a formula 1 or suberoylanilide hydroxamic acid shown in a formula 2.

The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and / or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases.

The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and / or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.

The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses pharmaceutical compositions comprising a recombinant stabilised variant ApoA1 protein or rHDL particles comprising such a protein, for use in the treatment of patients having reduced HDL or hampered reverse cholesterol transport.

The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and / or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases.

The invention belongs to the field of medicine and specifically discloses application of a dioscoreaceae plant dioscorea panthaica prain et burk and / or dioscorea nipponica makino steroidal total saponins extract in preparing a medicine for promoting reverse cholesterol transport and in preparing a medicine for regulating PPAR(gamma)-LXR(alpha)-ABCA1 gene pathway expression. Furthermore, the invention furtheralso discloses application in preparing medicines for preventing and treating atherosclerosis and medicines for treating the diseases on the pathological basis of atherosclerosis, based onthe effecton the effect basis ofon promoting the reverse cholesterol transport.

The invention discloses an application of andrographolide in preparation of an accelerator for promoting reverse cholesterol transport and an application of the andrographolide in medicament for resisting atherosclerosis. Experiments prove that andrographolide has significant effects of promoting intracellular reverse cholesterol transport and resisting atherosclerosis, is significant in curativeeffect, fast in effectiveness, low in toxic and side effects, especially free of influence on liver and kidney functions by andrographolide, is a safe, efficient and stable medicine or health care product for treating and conditioning cardiovascular diseases, is suitable for industrial production and is easy to popularize. Therefore, a new field is developed for application of andrographolide, anda novel drug source is provided for promoting intracellular reverse cholesterol transport, reducing intracellular cholesterol content, preventing and treating atherosclerosis and cardiovascular diseases.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and / or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases.

The invention discloses an application of promoting HDL synthesis in mice based on LCAT protein hydrosulfide modification to the preparation of drugs for the treatment of atherosclerosis. After the LCAT protein is modified by H2S, the activity of the LCAT protein can be enhanced, the maturation of HDL can be accelerated, and the atherosclerosis and other cardiovascular diseases can be relieved. The application demonstrates that an H2S donor given to a high-fat diet fed mice model can increase plasma HDL levels, and it is found that the key link in the process is the occurrence of hydrosulfidemodification of the LCAT protein; the application can provide basic research support for reverse cholesterol transport and correcting dyslipidemia, and a new target for drug development and treatmentof atherosclerosis and other diseases caused by the dyslipidemia can be provided.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (Apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (Apo A-I) synthetic peptide, or combination of an Apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various Apo A-I mimetic peptides, or endogenous Apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous Apo A-I.

The invention discloses the promotion of benserazide hydrochloride on a reverse cholesterol transport (RCT) way process so as to play a role in prevention and treatment of atherosclerosis. By establishing foam macrophage and liver cell model under an atherosclerosis condition, the invention studies the influence of benserazide hydrochloride on the expression of two crucial speed limiting receptors (ATP binding cassette transporter A1, scavenger receptor B1) in the reverse cholesterol transport (RCT) process, and finds that benserazide hydrochloride especially has very significant promoting effect on liver SRB1 and then promotes the last step of reverse cholesterol transport (RCT), thus having very important significance in prevention and treatment of atherosclerosis diseases. The study conforms to the development direction of China medicine modernization, and has important social significance and potential economic benefits in the fundamental research field and application research field.

The invention belongs to the field of biomedicine, and particularly relates to use of lecithin-cholesterol acyltransferase (LCAT) in preparing a drug or a healthcare product for treating and / or preventing the hepatic bone disease. According to the cell and animal experiments, the LCAT can realize reverse cholesterol transport of from osteocyte to hepatocyte, so that osteoporosis is relieved; meanwhile, an abnormal skeletal system in a chronic cirrhosis process further can be relieved, and bone density is increased, so that a brand-new choice and idea is provided for treating chronic hepatic bone disease, and the LCAT has a potential clinical application prospect.

The invention relates to a traditional Chinese medicine composition for regulating reverse cholesterol transport. The traditional Chinese medicine composition is prepared from, by weight, 30 parts ofraw radix astragali, 20 parts of radix salviae miltiorrhizae, 15 parts of trichosanthes kirilowii maxim and 12 parts of leeches. The invention also provides application of the traditional Chinese medicine composition. The traditional Chinese medicine composition directly acts on an LXRalpha-SREBP1-ABCA1 / G1 signal channel in arterial blood vessel macrophage, and further influences and reverses cholesterol efflux on the surface of the macrophage, so that the function of preventing generation and development of ASCVD is achieved. Clinical experiments verify that the traditional Chinese medicine composition can inhibit formation of plaques, improve the properties of plaques and improve the blood lipid condition of a patient, the side effect on the liver and kidneys is small, the safety is high, and atherosclerosis can be effectively treated; the number of raw material components is small, the cost is low, the method is simple, the curative effect is obvious, toxic and side effects are avoided, and the traditional Chinese medicine composition is easy to accept by the patient.

The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses pharmaceutical compositions comprising a recombinant stabilised variant ApoA1 protein or rHDL particles comprising such a protein, for use in the treatment of patients having reduced HDL or hampered reverse cholesterol transport.

The invention belongs to the field of pharmaceutical chemistry, and in particular relates to novel applications of pegylated curcumin derivative, especially the applications of the pegylated curcumin derivative in preparing medicines for preventing or treating fatty liver diseases and atherosclerosis. The experiment proves that the pegylated curcumin derivative can reduce the level of triglyceride in the blood, activate the phosphorylation of cyclic-AMP response element binding protein (CREB), negatively regulate nuclear transcription receptor PPAR gamma closely related to lipid metabolism, reduce the CD36 expression of the lever tissue caused by high fat diet, reduce the intake of fatty acid of the liver, reduce the lipid formation of the liver, and improve the fatty degeneration of the liver. The pegylated curcumin derivative further can improve the level of high density lipoprotein cholesterol, promote the reverse cholesterol transport, reduce the CD36 expression of macrophages, reduce the intake of oxidized low density lipoprotein, alleviate the bubblization of the macrophages, and reduce the deposition of lipid on the endangium and the formation of artery atherosclerotic plaque.